These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 12189530

  • 1. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

  • 2. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.
    Anderson CP, Keshelava N, Satake N, Meek WH, Reynolds CP.
    Med Pediatr Oncol; 2000 Dec; 35(6):659-62. PubMed ID: 11107141
    [Abstract] [Full Text] [Related]

  • 3. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
    Yang B, Keshelava N, Anderson CP, Reynolds CP.
    Cancer Res; 2003 Apr 01; 63(7):1520-6. PubMed ID: 12670899
    [Abstract] [Full Text] [Related]

  • 4. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
    Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP.
    J Pediatr Hematol Oncol; 2001 Nov 01; 23(8):500-5. PubMed ID: 11878777
    [Abstract] [Full Text] [Related]

  • 5. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA, Greene K, Ahmad S, Vistica DT.
    Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359
    [Abstract] [Full Text] [Related]

  • 6. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
    Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP.
    Pediatr Blood Cancer; 2015 Oct 15; 62(10):1739-46. PubMed ID: 26153194
    [Abstract] [Full Text] [Related]

  • 7. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.
    Anderson CP, Tsai J, Chan W, Park CK, Tian L, Lui RM, Forman HJ, Reynolds CP.
    Eur J Cancer; 1997 Oct 15; 33(12):2016-9. PubMed ID: 9516845
    [Abstract] [Full Text] [Related]

  • 8. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.
    Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP.
    Pediatr Blood Cancer; 2016 Aug 15; 63(8):1349-56. PubMed ID: 27092812
    [Abstract] [Full Text] [Related]

  • 9. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.
    Tagde A, Singh H, Kang MH, Reynolds CP.
    Blood Cancer J; 2014 Jul 18; 4(7):e229. PubMed ID: 25036800
    [Abstract] [Full Text] [Related]

  • 10. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC.
    Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674
    [Abstract] [Full Text] [Related]

  • 11. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
    Kable EP, Favier D, Parsons PG.
    Cancer Res; 1989 May 01; 49(9):2327-31. PubMed ID: 2706620
    [Abstract] [Full Text] [Related]

  • 12. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM.
    Clin Cancer Res; 1996 Dec 01; 2(12):1961-8. PubMed ID: 9816155
    [Abstract] [Full Text] [Related]

  • 13. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E.
    Mol Pharmacol; 1996 Jun 01; 49(6):1012-20. PubMed ID: 8649339
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
    Wu XX, Ogawa O, Kakehi Y.
    Int J Oncol; 2004 Jun 01; 24(6):1489-97. PubMed ID: 15138592
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A, Pellati A, De Mattei M, De Terlizzi F, Rossi CR, Campana LG.
    Anticancer Drugs; 2015 Mar 01; 26(3):284-92. PubMed ID: 25514113
    [Abstract] [Full Text] [Related]

  • 16. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan 01; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of cross-resistance between radiation and antineoplastic drugs.
    Ozols RF, Masuda H, Hamilton TC.
    NCI Monogr; 1988 Jan 01; (6):159-65. PubMed ID: 3352759
    [Abstract] [Full Text] [Related]

  • 18. Intercellular transfer of drug resistance.
    Frankfurt OS, Seckinger D, Sugarbaker EV.
    Cancer Res; 1991 Feb 15; 51(4):1190-5. PubMed ID: 1997161
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
    Papadopoulou MV, Ji M, Khan SH, Bloomer WD.
    Oncol Res; 1999 Feb 15; 11(8):345-57. PubMed ID: 10803738
    [Abstract] [Full Text] [Related]

  • 20. Promising effects of the 4HPR-BSO combination in neuroblastoma monolayers and spheroids.
    Cuperus R, van Kuilenburg AB, Leen R, Bras J, Caron HN, Tytgat GA.
    Free Radic Biol Med; 2011 Sep 15; 51(6):1213-20. PubMed ID: 21741474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.